How did Tchaikapharma High Quality Medicines reduce the cost of treatment?
We conducted a study with 1,100 patients with cardiovascular diseases. Their admission and discharge therapies were evaluated from:
a financial point of view – cost of treatment
a medical point of view – compliance with the ESC guidelines
an organizational point of view – how to improve the habits for adhering to the assigned therapy
The results:
– 37.83% of the admission therapies complied with the ESC guidelines at an average price of BGN 46.87
– 84.13% of discharge therapies, including those with medicines of Tchaikapharma, complied with the ESC guidelines at an average price of BGN 31.80
– Reported improvement of over 23% in therapy adherence after the follow-up campaign and a positive therapeutic effect of such adherence.
The conclusion:
Following strictly the ESC guidelines and prescribing Tchaikapharma medicines may reduce the cost of treatment by >32% compared to the current treatment practices in Bulgaria.
| Diagnosis | Treatment | Cost of treatment for the patient [BGN] |
| Hypertension + CAD
without clopidogrel |
2 pharmaceuticals | 25.19 |
| 3 pharmaceuticals | 47.9 | |
| 4 pharmaceuticals | 84.31 | |
| 5 pharmaceuticals | 165.83 | |
| 6 pharmaceuticals | 279.76 | |
| Hypertension + Heart Failure | 2 pharmaceuticals | 14.14 |
| 3 pharmaceuticals | 27.74 | |
| 4 pharmaceuticals | 48.43 | |
| 5 pharmaceuticals | 85.13 | |
| 6 pharmaceuticals | 133.78 | |
| CAD + Heart Failure
without clopidogrel |
2 pharmaceuticals | 22.52 |
| 3 pharmaceuticals | 42.81 | |
| 4 pharmaceuticals | 68.72 | |
| 5 pharmaceuticals | 120.42 | |
| 6 pharmaceuticals | 196.45 |
Source: Vekov T, Djambazov S. DETAILED ANALYSIS OF COMPLEX DRUG THERAPIES EFFICACY IN TREATMENT OF CARDIOVASCULAR PATIENTS; Modern Medicine, 2008, 3(59), 12-18
| Diagnosis | Cost of treatment [BGN] |
| Hypertension | 27.73 |
| CAD | 52.47 |
| Heart Failure | 16.95 |
| Hypertension + CAD | 120.6 |
| Hypertension + Heart Failure | 61.85 |
| CAD + Heart Failure | 90.19 |
Source: Vekov T, Djambazov S. DETAILED ANALYSIS OF COMPLEX DRUG THERAPIES EFFICACY IN TREATMENT OF CARDIOVASCULAR PATIENTS; Modern Medicine, 2008, 3(59), 12-18
The average reimbursement value paid by the National Health Insurance Fund is 25%, while co-payment by the patient is 75%. Considering the average cost of treatment in Bulgaria, this means cardiovascular patients incur costs amounting to 11% of the average salary and 21% of the average pension. Therefore, the majority of patients find it difficult to purchase and adhere to an expensive therapy, which most of the times is even not the most appropriate one.
By offering affordable molecules for therapeutic strategies approved by the European Society of Cardiology, Tchaikapharma is bridging the gap between the guidelines and current therapeutic practice in the country.